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	 Enantio	 separation	of	 the	 local	 anesthetic	drugs;	 ropivacaine	 (Rop),	 bupivacaine	 (Bup)
and	potential	organic	 impurities	(2,6‐Dimethylaniline,	2,6‐DMA)	were	accomplished	on
HPTLC	using	mucopolysaccharide	selector	(Chondroitin)	as	chiral	mobile	phase	additive
(CMPA).	 The	 enantioseparation	 was	 achieved	 in	 acetonitrile:water:methanol	 (16:3:1,
v:v:v)	 containing	 0.25%	 chondroitin	 as	 chiral	 mobile	 phase	 additive.	 The	 influence	 of
separation	 conditions,	 including	 type	 and	 concentration	 of	 chiral	 selector,	 organic
modifiers	and	temperatures	on	enantioseparation	were	evaluated.	The	enantioselective
HPTLC	method	was	validated	to	control	the	enantiomeric	purity	of	the	(S)‐enantiomers
(S‐Rop	 and	 S‐Bup);	 the	 active	 ingredients	 contained	 in	 drug	 products.	 In	 these
conditions,	 linearity	 over	 the	 concentration	 range,	 1.0‐10.0	 µg/spot	 for	 each	 (R)‐
enantiomer	and	1.0‐8.0	µg/spot	for	2,6‐DMA	main	organic	impurity	were	obtained.	The
detection	limits	are	less	than	0.6	µg/spot	of	chiral	and	organic	impurities.	The	intra	and
inter‐day	assay	precision	was	less	than	3.0%	(RSD%).	
Validation	
2,6‐Dimethylaniline	
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Ropivacaine	enantiomers	
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1.	Introduction	
	
It	 is	 well	 known	 that	 for	 chiral	 drugs,	 pharmaceutical	
activity	 resides	 mostly	 in	 one	 of	 the	 enantiomers,	 and	
unwanted	side	effects	or	even	toxic	effects	are	often	observed	
for	the	other	enantiomer	[1].	From	this	reason,	the	separation	
of	 enantiomers	 is	 an	 important	 subject	 in	 pharmaceutical	
analysis.	 Bupivacaine	 is	 a	 potent	 local	 anaesthetic;	 has	 been	
marketed	as	a	50:50	racemic	mixture	of	 two	enantiomers	 [2].	
The	molecular	structure	of	this	highly	lipid	soluble	and	protein	
bound	compound	contains	a	chiral	centre	in	the	piperidine	ring,	
resulting	in	two	optically	active	stereoisomers.	Accordingly;	the	
new	 long‐acting	 local	 anaesthetics,	 ropivacaine	 and	
levobupivacaine	 have	 been	 developed	 as	 safer	 alternatives	 to	
bupivacaine.	 Ropivacaine	 and	 Levobupivacaine	 are	 S(+)	
enantiomers	 of	 two	 different	 molecules,	 1‐propyl‐2’6’‐
pipecoloxylidide	 and	 1‐butyl‐2’,6’‐pipecoloxylidide,	 respecti‐
vely	 [3,4]	 and	 their	 potential	 organic	 impurity	 2,6‐DMA	 are	
shown	in	Figure	1.		
The	 mechanism	 of	 bupivacaine	 induced	 cardiac	
arrhythmias	 may	 result	 from	 its	 inhibitory	 effect	 on	 sodium	
channel	 current.	 The	 bupivacaine	 induced	 block	 of	 the	
inactivated	 state	 of	 sodium	 channels	 displayed	 stereo	
selectivity	 with	 R(–)	 enantiomer	 interacting	 faster	 and	 more	
potently.	 Lower	 potency	 of	 S(+)	 bupivacaine	 to	 block	 a	
particular	subset	of	cardiac	sodium	channels	might	explain	 its	
lower	cardio	toxicity	[5,6].		
Different	 analytical	 methods	 have	 been	 developed	 for	
separation	 of	 enantiomers.	 Chiral	 separation	 by	 capillary	
electrophoresis	 (CE)	 using	 a	 variety	 of	 chiral	 selectors	 have	
been	 reported	 [7‐10].	 Among	 them	 cyclodextrins	 and	 their	
derivatives	 are	 the	 most	 frequently	 employed	 [11].	 Recently	
mucopolysaccharides	 have	 also	 been	 found	 to	 be	 effective	 as	
chiral	selectors	 in	CE	[12,13].	These	substances	have	only	 low	
absorbance	 in	 the	 UV	 region,	 which	 is	 beneficial	 for	 high	
detection	 sensitivity.	 Methods	 based	 on	 high	 performance	
liquid	 chromatography	 (HPLC)	 using	 chiral	 stationary	 phases	
have	 been	 most	 widely	 used	 for	 analysis	 of	 both	 drug	
enantiomers	 in	 pharmaceutical	 preparations	 and	 biological	
fluids	 [14‐17].	 Various	 kinds	 of	 columns	 have	 been	 used.	
Moreover	derivatives	CDs	impregnated	to	silica	gel	normal	TLC	
plates	 were	 reported	 for	 chiral	 separation	 of	 both	 drugs	
[18,19].	 In	 the	 literature,	 there	 is	 no	 reference	 for	 direct	
enantiomeric	 resolution	 and	 determination	 of	 Rop,	 Bup	 and	
their	 chiral	 (–)R	 and	 potential	 organic	 impurities	 (2,6‐DMA)	
using	mucopolysaccharide	as	chiral	mobile	phase	additive.		
The	 present	 work	 describes	 direct	 and	 economic	 HPTLC‐
densitometric	method	for	enantioseparation	and	determination	
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of	 (–)	 R‐	 and	 (+)	 S‐Rop‐HCl	 and	 Bup‐HCl	 and	 their	 potential	
organic	 impurity	 2,6‐DMA	 using	 mucopolysacharid	
(Chondroitin)	 as	 chiral	 mobile	 phase	 additive	 at	 different	
temperatures.	Moreover	 iodine	vapor	and	UV	 lamp	were	used	
for	the	detection	of	chiral	and	organic	impurities	of	both	drugs.	
This	method	may	become	the	method	of	choice	compared	with	
other	 techniques	 for	 economic	 fast	 routine	 analysis	 of	 both	
drugs.	
	
	
	
Figure	 1.	 The	 chemical	 structure	 of	 (R)‐	 and	 (S)‐bupivacaine,	 ropivacaine	
and	their	potential	organic	impurity	2,6‐dimethyl	aniline.	
	
2.	Experimental	
	
2.1.	Chemicals	and	reagents	
	
All	 chemicals	 were	 of	 analytical	 grade	 if	 not	 stated	
otherwise.	 (+)S‐Ropivacaine	 and	 (‐)R‐ropivacaine	were	 kindly	
supplied	by	Asra‐Zenica,	Co.,	UK.	Naropin	vial	were	 labeled	 to	
contain	 7.5	 mg/mL	 (S)‐ropivacaine	 per	 vial	 was	 purchased	
from	 the	market.	 (+)S‐Bupivacaine	and	 (‐)R‐bupivacaine	were	
kindly	 supplied	 by	 Astra‐Zenica,	 Co.	 UK.	 Bucain	 vial	 were	
labeled	to	contain	0.5%	bupivacaine	per	vial	(Delta	select,	Co.,	
Egypt)	 was	 purchased	 from	 the	 market.	 2,6‐Dimethylaniline	
(98.00%)	 was	 purchased	 from	 Merck	 Schuchardt	 OHG,	 Co.,	
Germany.	 Chondroitin	 sulfate	 (Bovine)	 BN	 20/20226	 was	
kindly	 supplied	 from	 Unipharma	 Co.	 Egypt.	 Methanol,	
acetonitrile	 and	 dichloromethane	 were	 obtained	 from	 Lab.	
Scan,	Ireland.		
	
2.2.	Equipment	
	
HPTLC	plates	(20×20	cm2,	aluminium	plates	precoated	with	
0.2	mm	Nano‐Silica	gel	60	with	fluorescence	indicator	F254	were	
purchased	 from	 Merck,	 Co.,	 Germany.	 The	 samples	 were	
applied	 to	 the	 plates	 with	 25	 μL	 Hamilton	 microsyringe.	 UV	
short	 wavelength	 (254	 nm)	 lamp	 (Desaga,	 Germany)	 and	
Shimadzu	dual	wavelength	flying	spot	densitometer,	Model	CS‐
9301,	 PC	 were	 used.	 The	 experimental	 conditions	 of	 the	
measurements	were	as	follows:	wavelength	=	220	nm	for	each	
(–)R‐	 and	 (+)S‐	 enantiomers	 and	 2,6‐dimethylaniline,	 photo	
mode	=	reflection,	scan	mode	=	zigzag,	and	swing	width	=	10.	
	
2.3.	Standard	solutions		
	
Standard	stock	solutions	(1	mg/mL)	of	each	(‐)R‐	and	(+)S‐,	
Rop‐HCl	 ,	Bup‐HCl	enantiomers,	and	2,6‐(DMA)	were	prepared	
by	 dissolving	 appropriate	 amounts	 of	 each	 in	 methanol.	 The	
stock	 solutions	 were	 subsequently	 used	 to	 prepare	 working	
standards	in	concentration	ranges	of	0.10‐1.00	mg/mL	for	each	
single	isomer	(‐)R‐	and	(+)S‐,	and	0.10‐0.80	mg/mL	of	potential	
organic	impurity	by	further	dilution	with	methanol.	
	
2.4.	Chromatographic	conditions	
	
Cleaned,	dried	and	paper‐lined	glass	chambers	(12×24×24	
cm)	were	used	for	developing	chromatograms.	They	were	pre‐
equilibrated	 with	 developer	 for	 10	 minutes.	 The	 normal	 TLC	
plates	were	prepared	by	 running	 the	mobile	 phase	 consisting	
of,	 acetonitrile:water:methanol	 in	 ratio	 of	 (16:3:1,	 v:v:v)	
containing	 0.25%	 (w:v)	 of	 chiral	 selector	 (chondroitin)	 in	 the	
usual	 ascending	 way	 and	 air	 dried.	 For	 detection	 and	
quantification,	20	μL	of	each	racemic	solution	and	10	μL	of	their	
single	 isomer	 (–)R‐	 and	 (+)S‐,	 and	 2,6‐DMA	 of	 different	
concentrations	 within	 the	 quantification	 range	 were	 applied	
side‐by‐side	 as	 separate	 compact	 spots	 20	 mm	 apart	 and	 10	
mm	 from	 the	 bottom	 of	 the	 HPTLC	 plates	 using	 a	 25	 µL	
Hamilton	micro	 syringe.	 The	 chromatograms	were	 developed	
up	 to	 8	 cm	 in	 the	 usual	 ascending	 way.	 The	 plates	 were	
visualized	at	254	nm	and	scanned	for	R	and	S	isomers	and	2,6‐
DMA	 at	 220	 nm	 for	 both	 drugs,	 by	 using	 the	 instrumental	
parameters	mentioned	above.		
	
2.5.	Synthetic	mixtures	
	
Synthetic	mixtures	of;	 (‐)R‐	and	(+)S‐,	and	2,6‐DMA	within	
the	 quantification	 range	 of	 each	 drug	 were	 prepared	 and	
chromatographed	 according	 to	 the	 procedure	 mentioned	
above.		
	
2.6.	Sample	preparation	
	
Equivalent	 milliliters	 of	 each	 Naropin	 or	 Bucain	 vial	
equivalent	 to	 50	 mg	 of	 (+)S‐Rop	 or	 Bup,	 respectively,	 were	
extracted	 with	 dichloromethane.	 Aliquots	 of	 10	 mL	 of	 each	
were	 transferred	 to	 two	 beakers,	 air	 dried	 and	 transferred	
quantitatively	 to	 10	 mL	 volumetric	 flasks	 and	 diluted	 with	
methanol.	Then	the	procedure	was	completed	as	described	for	
the	construction	of	calibration	graphs.	
	
2.7.	Method	validation	
	
2.7.1.	Linearity	of	(‐)R‐,	(+)S‐enantiomers	and	2,6‐DMA	
	
Linearity	was	assessed	by	preparing	six	calibration	sample	
solutions	 of	 each	 isomer	 and	 2,6‐DMA	 in	 the	 concentration	
range	of	0.100‐1.00	mg/mL	in	methanol	and	five	calibration	of	
organic	impurity	in	concentration	range	of,	0.100‐0.80	mg/mL	
in	methanol	for	working	solutions.	
Regression	 curves	 were	 obtained	 by	 plotting	 peak	 areas	
versus	concentration,	using	the	least	squares	method.	Linearity	
was	 checked	 for	 three	 consecutive	 days	 in	 the	 same	 concent‐
ration	range	from	the	same	stock	solutions.		
	
2.7.2.	Limits	of	detection	and	quantification	
	
The	 limit	 of	 detection	 (LOD)	 represents	 the	 concentration	
of	analyte	that	would	yield	a	signal‐to‐noise	ratio	of	three.	The	
limit	 of	 quantification	 (LOQ)	 represents	 the	 lowest	 concent‐
ration	of	calibration	curve	[20,21].	
The	precision	of	the	developed	chiral	method	for	each	(‐)R‐	
and	(+)S‐	enantiomers	at	limit	of	quantification	was	checked	by	
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Table	1.	Effect	of	mobile	phase	on	resolution	of	the	enantiomers	of	(RS)‐ropivacaine	and	(RS)‐bupivacaine	hydrochloride.	
Mobile	phase	
CH3CN:H2O:CH3OH	
Rop	hRF	 			hRF(R)/hRF(S)	 Bup	hRF	 			hRF(R)/hRF(S)	
R	 S	 R S
16:3:1	 60	 41 		1.50 62 40 			1.55	
16:4:1	 84	 60 		1.40 58 47 			1.23	
17:4:0	 51	 36 		1.41 61 45 			1.36	
	
	
analyzing	 five	 test	 solutions	 of	 each	 enantiomer	 and	 2,6‐DMA	
prepared	 at	 LOQ	 and	 calculating	 the	 percentage	 of	 relative	
standard	deviation	of	the	peak	area.		
	
2.7.3.	Precision	
	
Method	 reproducibility	 was	 determined	 by	 measuring	
repeatability	 and	 intermediate	 precision	 (between‐	 day	
precision)	 of	 retardation	 factor	 (RF)	 and	 peak	 areas	 for	 each	
enantiomer	 and	 2,6‐DMA.	 In	 order	 to	 determine	 the	
repeatability	of	the	method,	freshly	prepared	solutions	of	(–)R‐	
and	 (+)S‐	 of	 each	 drug	 and	 2,6‐DMA,	 in	 triplicate	 at	 concent‐
rations	 of	 2,	 4	 and	 8	 µg/spot	 (n	 =	 9)	 was	 carried	 out.	 The	
intermediate	precision	was	also	evaluated	over	 three	days,	by	
performing	triplicate	of	the	same	concentration	each	day.	
	
2.7.4.	Accuracy	
	
The	 accuracy	 was	 determined	 by	 application	 of	 standard	
addition	 technique.	 Synthetic	 mixtures	 of	 the	 drug	 products	
and	known	amount	of	each	(‐)R‐	and	(+)S‐enantiomers	and	2,6‐
DMA	within	the	quantification	range	were	performed.	
	
2.7.5.	Specificity	
	
Specificity	 is	 the	 ability	 of	 the	 method	 to	 measure	 the	
analyte	response	in	the	presence	of	interfering	substances.	For	
specificity	determination,	 synthetic	mixtures	 of	 each	 (+)S‐Rop	
and	Bup	 and	 their	 chiral	 (‐)R	 and	 organic	 impurities	2,6‐DMA	
were	performed	and	the	recovery	percentage	was	determined.		
	
2.7.6.	Robustness		
	
The	robustness	of	the	method	is	the	ability	of	the	method	to	
remain	 unaffected	 by	 small	 changes	 in	 parameters	 such	 as	
mobile	phase	composition,	temperature,	concentration	of	chiral	
selector	and	the	saturation	time	of	mobile	phase.	To	determine	
robustness	 of	 the	 method,	 experimental	 conditions	 were	
purposely	 altered	 and	 chromatographic	 resolution	 between						
(‐)R‐	and	(+)S‐enantiomers	and	their	potential	organic	impurity	
were	evaluated.		
	
2.7.7.	Solution	stability	
	
Stability	 of	 R‐	 and	 S‐	 isomers	 in	 solution	 at	 analyte	
concentration	 was	 studied	 by	 keeping	 the	 solution	 in	 tightly	
capped	volumetric	 flask	 at	 room	 temperature	on	a	 laboratory	
bench	 for	 7	 days.	 Content	 of	 (‐)R‐	 and	 (+)S‐	 enantiomers	 and	
2,6‐DMA	 were	 checked	 for	 7	 days	 interval	 up	 to	 the	 study	
period.		
	
3.	Results	and	discussion		
	
3.1.	Optimization	of	chromatographic	conditions		
	
Chiral	analysis	of	 (+)S‐Rop	 and	Bup	 is	of	great	 importance	
since	only	the	(S)‐enantiomer	is	used	when	ropivacaine	is	given	
as	a	drug.	The	amount	of	 (‐)R‐enantiomer	should	be	as	 low	as	
possible.	Using	the	proposed	method,	 it	was	possible	to	detect	
an	 impurity	 of	 less	 than	 0.6	 µg/spot	 of	 (‐)R‐Rop	 and	 (‐)R‐Bup	
present	in	(+)S‐Rop	and	(+)S‐Bup,	respectively.	The	aim	of	this	
work	 is	 to	 develop	 validated	 chiral	 HPTLC	 method	 for	
enantioseparation	and	accurate	quantification	of	both	(+)S‐	and	
(‐)R‐	 enantiomers	 and	 their	 organic	 impurity	 (2,6‐DMA).	
Racemic	 mixture	 solution	 of	 1	 mg/mL	 prepared	 in	 methanol	
was	used	in	the	method.	To	develop	rugged	and	suitable	HPTLC	
method	 for	 the	 separation	 of	 Rop	 and	 Bup	 enantiomers,	 and	
2,6‐DMA,	 different	 mobile	 phases,	 chiral	 selectors	 and	 TLC	
plates	at	different	temperatures	were	tried.		
Several	 trial	 runs	 were	 systematically	 performed	 using	
different	 ratios	 of	 the	 solvent	 system	 acetonitrile‐methanol‐
water.	 The	 successful	 solvent	 system	 was	 acetonitrile:	
methanol:water	 (16:1:3,	 v:v:v)	 containing	 0.25%	 chondrointin	
as	CMPA,	as	shown	in	Table	1.		
The	results	are	average	of	at	least	12	identical	runs.	Normal	
HPTLC	plates	showed	good	resolution	with	RF	=	0.62	and	RF	=	
0.60	for	R‐	and	RF	=	0.40	and	RF	=	0.42	for	S‐forms	for	Rop	and	
Bup,	respectively,	and	0.87	for	their	potential	organic	impurity	
2,6‐DMA	as	shown	in	Figure	2.	
	
Rop
R S DMA Mix
Bup
R S DMA Mix
	
Figure	 2.	 Thin	 layer	 chromatograms	 showing	 resolution	 of	 (R)‐	 and	 (S)‐
ropivacaine	 and	 bupivacaine	 (10	 μg/spot),	 and	 their	 potential	 organic	
impurity	 2,6‐DMA,	 mobile	 phase	 acetonitrile:methanol:water	 (16:1:3,	 v:v:v)	
containing	0.25%	chondroitin	as	CMPAs,	Temperature:	20	°C,	pH	=	6.5.
	
In	 order	 to	 achieve	 the	 separation	 of	 ropivacaine	 and	
bupivacaine	 enantiomeric	 forms,	 different	 concentrations	 of	
chondroitin	were	tried	in	concentration	range,	0.1‐0.5	g%,	and	
the	 optimal	 concentration	 was	 achieved	 with	 0.25	 g%,	 the	
results	are	shown	in	Figure	3.		
	
	
	
Figure	3.	Effect	of	chondroitin	concentration	on	enantiomeric	resolution	of	
(RS)‐ropivacaine	and	(RS)‐bupivacaine	(10	μg/spot).	
	
Chiral	 interaction	 between	 the	 analyte	 and	 chiral	 selector	
are	 known	 to	 be	 affected	 by	 temperature	 [22].	 In	 our	 study	
different	temperatures;	4,	20	and	40	°C	were	studied.	The	best	
resolution	 was	 obtained	 at	 20±2	 °C	 as	 shown	 in	 Figure	 4.	
Decrease	 in	 temperature	 (4	 °C)	 showed	 no	 significant	
difference,	 whereas	 increase	 in	 temperature	 showed	 a	
tendency	for	low	selectivity.		
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Table	2.	Results	from	validation	of	the	method.	
Parameters	 Values	
Ropivacaine Bupivacaine 2,6‐Dimethyl	aniline
Repeatability	(RSD[%],	n	=	9)	 	 	 	
RF(R)	enantiomer	 0.07	 0.06	 0.09	
RF(S)	enantiomer	 0.03 0.02 	
Peak	area	(R)‐enantiomer	 1.70 2.83 3.81	
Peak	area	(S)‐enantiomer	 2.32 1.71 	
Intermediate	precision	(RSD	[%],	n	=	27)	 	
RF	(R)‐enantiomer	 0.17 0.16 0.17	
RF	(S)‐enantiomer	 0.23 0.21 	
Peak	area	(R)‐enantiomer	 1.70	 2.83	 4.81	
Peak	area	(S)‐enantiomer	 2.32	 1.71	 	
LOD	 	 	 	
Limit	of	detection	[μg/spot]	for	(R)‐enantiomer	 0.50 0.57 0.60	
Limit	of	detection	[μg/spot]	for	(S)‐enantiomer	 0.42	 0.30	 	
LOQ	 	
Limit	of	quantification	[μg/spot]	for	(R)‐enantiomer	 1.00 1.00 1.00	
Precision	(RSD	[%])	 2.35 3.75 1.59	
Limit	of	quantification	[μg/spot]	for	(S)‐enantiomer	 1.00 1.00 	
Precision	(RSD	[%])	 2.77 2.56 	
Linearity	for	(R)‐enantiomer	 	
Calibration	range	[μg/spot]	 1‐10	 1‐10	 1‐8	
Calibration	points	 6 6 5	
Correlation	coefficient	 0.9993	 0.9995	 0.9997	
SE	of	slope	[%]	 7.65	 6.90	 11.23	
SE	of	intercept	[%]	 46.55	 42.25	 55.27	
Linearity	for	(S)‐enantiomer	 	
Calibration	range	[μg/spot]	 1‐10 1‐10 	
Calibration	points	 6 6 	
Correlation	coefficient	 0.9994 0.9994 	
SE	of	slope	[%]	 8.72	 11.36 	
SE	of	intercept	[%]	 48.86 103.56 	
	
	
Table	3.	Robustness	of	the	method.	
Conditions	 Ropivacaine	 Bupivacaine	
Selectivity
hRF	(R)/hRF	(S)	
Selectivity	
hRF	(R)/hRF	(S)	
Concentration	of	chiral	selector	[g%]	
0.30	 1.30 1.74	
0.25	 2.17 1.78	
0.20	 1.54 1.67	
Mobile	phase	composition	
Acetonitrile:methanol:water	 	 	
16:0.8:3	 1.51	 1.51	
16:1.0:3	 2.17	 1.78	
16:1.2:3	 1.80 1.40	
Temp	[oC]	 	 	
23	 1.74 1.70	
25	 1.80 2.06	
27	 1.70 1.23	
Saturation	time	[min]	
8	 2.17 1.87	
10	 2.05 2.06	
12	 2.01 1.90	
	
	
According	 to	 the	 experimental	 conditions	 a	 control	
stationary	without	 CMPA	 spotted	with	 the	 tested	 compounds	
were	eluted	and	resulted	in	no	resolution	of	racemic	mixtures.	
	
	
	
Figure	 4.	 Effect	 of	 temperature	 on	 enantiomeric	 resolution	 of	 (RS)‐
ropivacaine	and	(RS)‐bupivacaine	(10	μg/spot).	
	
	
	
3.2.	Method	validation		
	
In	 the	 repeatability	 study	 the	 relative	 standard	 deviation	
(RSD)	for	the	retardation	factor	for	(+)S‐,	(‐)R‐enantiomrs	and	
2,6‐DMA	and	of	the	peak	area	was	less	than	3.0%	as	presented	
in	 Table	 2.	 In	 the	 intermediate	 precision	 study,	 results	 show	
that	 RSD	 values	 were	 in	 the	 same	 order	 of	 magnitude	 than	
those	obtained	for	repeatability	as	presented	in	Table	2.	
The	 limit	 of	 detection	 (LOD)	was	 estimated	 to	 be	 0.5	 and	
0.6	 µg/spot	 for	 (+)S‐	 and	 (‐)R‐enantiomers,	 whereas	 limit	 of	
quantification(LOQ)	 was	 the	 lowest	 concentration	 of	
calibration	 curve	 as	 stated	 in	 Table	 2.	 Good	 linearity	 was	
observed	for	(+)S‐	and	(‐)R‐enantiomers	of	both	drugs	over	the	
concentration	range	of	1.0‐10	µg/spot	as	presented	in	Table	2.	
Linearity	was	checked	for	(+)S‐	and	(‐)R‐enantiomers	over	the	
same	 concentration	 range	 for	 three	 consecutive	 days.	 The	%	
RSD	of	the	slope	and	y‐intercept	of	the	calibration	curves	were	
shown	in	Table	2.	
The	 resolution	 between	 (+)S‐,	 (‐)R‐enantiomers	 and	 2,6‐
DMA	 was	 greater	 than	 1.51	 under	 all	 separation	 conditions	
tested,	demonstrating	sufficient	robustness	Table	3.	
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Table	4.	Results	of	laboratory	prepared	mixtures	
Ropivacain	(Conc.	µg/spot)	 Bupivacaine	(Conc.	µg/spot)	
Ratio	 Recovery	(n	=	3)	
%±RSD	of	S‐ropivacaine		
Ratio Recovery	(n	=	3)	
%±RSD	of	levobupivacaine		R	 S	 2,6‐DMA	 R S 2,6‐DMA
4	 4	 2	 99.50±1.04		 4	 4	 2	 99.60±1.55	
1	 8	 1	 101.00±1.89		 1	 8	 1	 98.00±1.70	
1	 6	 2	 100.75±1.77		 1 6 2 100.50±2.00	
	
	
Table	5.	Application	of	the	proposed	method	for	determination	of	robivacaine	and	bupivacaine	in	their	drug	products	and	the	recovery	results	of	addition	of	R	
and	S	enantiomers.	
Accuracy	(RE	c	%)Precision	(RSD) Recovery	%	bEnantiomers	addedRecovery	%	of	label	claim	aDrug	products 
R(R) Naropin	 vial	 labeled	 to	 contain	
7.5	 mg/mL	 (S)	 ropivacaine	 per	
vial	
3.00	1.78	 97.00	2	
4	
8	
S 
2	
1.0	
(S) 
98.0	
1.65	1.90	 98.35 
99.70		
99.86 
0.30	 1.65		
0.14 1.54	 
‐0.50	1.78	 100.50	4
1.47	 1.66 98.53		8	
R(R) Bucain	 vial	 labeled	 to	 contain	
0.5%	per	vial	(±)	bupivacaine 2.00 2.00 98.002	
4	
8	
S	
48.8	
(S) 
51.0	
0.40 1.70 99.60
‐1.00 1.54 101.00 
0.20 1.23 99.802	
‐1.001.80 101.004
‐0.801.60 100.808
a	n=5.	
b	n=3.		
c	Relative	error,	{(measured	mean	value	‐	nominal	value)/nominal	value}×100.	
	
	
The	 specificity	 of	 the	 method	 was	 assessed	 by	 analyzing	
synthetic	mixtures	of	(+)S‐form	and	its	chiral	(‐)R‐	and	organic	
impurities	(2,6‐DMA)	in	different	ratios	as	shown	in	Table	4.	
The	 accuracy	 was	 assessed	 by	 applying	 the	 standard	
additions	 technique.	 Satisfactory	 results	 were	 obtained	 and	
were	in	good	agreement	with	the	labeled	claim,	as	presented	in	
Table	5.	
No	 significant	 change	 in	 the	 (+)S‐	 and	 (‐)R‐	 content	 was	
observed	 in	 (Rac)	Rop	 and	 (Rac)	Bup	samples	during	solution	
stability.	Hence,	 (+)S‐,	 (‐)R‐	and	2,6‐DMA	 samples	solution	are	
stable	for	at	least	7	days	at	25±2	°C.	
	
4.	Conclusion		
	
Inexpensive	 and	 environment	 friendly	 densitometric‐
HPTLC	 method	 was	 described	 for	 enantioseparation	 and	
determination	of	Rop,	Bup	and	their	impurities;	chiral	(‐)R‐	and	
organic	 (2,6‐DMA).	 The	 developed	 method	 may	 become	 the	
method	 of	 choice,	 compared	 with	 other	 chromatographic	
techniques	 for	 chiral	 discrimination	 and	 fast	 routine	
enantiomeric	 purity	 assessment.	 The	method	was	 completely	
validated	 showing	 satisfactory	 data	 for	 all	 the	 method	
validation	parameters	tested.	
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